General Information:

Id: 4,276
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Schizophrenia - [OMIM]
Homo sapiens
article/cited
Reference: Cabaleiro T et al.(2013) Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects Hum Psychopharmacol 28: 205-214 [PMID: 23559402]

Interaction Information:

Comment Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors: serotonin 5HT2A/2C; dopamine D1, D2, D3, and D4; muscarinic M1, M2, M3, M4, and M5; histamine H1; and adrenergic (alpha-1) receptors. The antipsychotic activity of olanzapine is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism of muscarinic, histamine, and adrenergic receptors may explain some adverse effects, such as anticholinergic effects, somnolence, and hypotension. (cited information)
Formal Description
Interaction-ID: 43738

drug/chemical compound

Olanzapine

decreases_activity of

gene/protein

HTR2A

Drugbank entries Show/Hide entries for Olanzapine or HTR2A
Comment Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors: serotonin 5HT2A/2C; dopamine D1, D2, D3, and D4; muscarinic M1, M2, M3, M4, and M5; histamine H1; and adrenergic (alpha-1) receptors. The antipsychotic activity of olanzapine is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism of muscarinic, histamine, and adrenergic receptors may explain some adverse effects, such as anticholinergic effects, somnolence, and hypotension. (cited information)
Formal Description
Interaction-ID: 43745

drug/chemical compound

Olanzapine

decreases_activity of

gene/protein

HTR2C

Drugbank entries Show/Hide entries for Olanzapine or HTR2C
Comment Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors: serotonin 5HT2A/2C; dopamine D1, D2, D3, and D4; muscarinic M1, M2, M3, M4, and M5; histamine H1; and adrenergic (alpha-1) receptors. The antipsychotic activity of olanzapine is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism of muscarinic, histamine, and adrenergic receptors may explain some adverse effects, such as anticholinergic effects, somnolence, and hypotension. (cited information)
Formal Description
Interaction-ID: 43746

drug/chemical compound

Olanzapine

decreases_activity of

gene/protein

DRD1

Drugbank entries Show/Hide entries for Olanzapine or DRD1
Comment Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors: serotonin 5HT2A/2C; dopamine D1, D2, D3, and D4; muscarinic M1, M2, M3, M4, and M5; histamine H1; and adrenergic (alpha-1) receptors. The antipsychotic activity of olanzapine is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism of muscarinic, histamine, and adrenergic receptors may explain some adverse effects, such as anticholinergic effects, somnolence, and hypotension. (cited information)
Formal Description
Interaction-ID: 43747

drug/chemical compound

Olanzapine

decreases_activity of

gene/protein

DRD2

Drugbank entries Show/Hide entries for Olanzapine or DRD2
Comment Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors: serotonin 5HT2A/2C; dopamine D1, D2, D3, and D4; muscarinic M1, M2, M3, M4, and M5; histamine H1; and adrenergic (alpha-1) receptors. The antipsychotic activity of olanzapine is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism of muscarinic, histamine, and adrenergic receptors may explain some adverse effects, such as anticholinergic effects, somnolence, and hypotension. (cited information)
Formal Description
Interaction-ID: 43748

drug/chemical compound

Olanzapine

decreases_activity of

gene/protein

DRD3

Drugbank entries Show/Hide entries for Olanzapine or DRD3
Comment Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors: serotonin 5HT2A/2C; dopamine D1, D2, D3, and D4; muscarinic M1, M2, M3, M4, and M5; histamine H1; and adrenergic (alpha-1) receptors. The antipsychotic activity of olanzapine is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism of muscarinic, histamine, and adrenergic receptors may explain some adverse effects, such as anticholinergic effects, somnolence, and hypotension. (cited information)
Formal Description
Interaction-ID: 43749

drug/chemical compound

Olanzapine

decreases_activity of

gene/protein

DRD4

Drugbank entries Show/Hide entries for Olanzapine or DRD4
Comment Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors: serotonin 5HT2A/2C; dopamine D1, D2, D3, and D4; muscarinic M1, M2, M3, M4, and M5; histamine H1; and adrenergic (alpha-1) receptors. The antipsychotic activity of olanzapine is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism of muscarinic, histamine, and adrenergic receptors may explain some adverse effects, such as anticholinergic effects, somnolence, and hypotension. (cited information)
Formal Description
Interaction-ID: 43750

drug/chemical compound

Olanzapine

decreases_activity of

gene/protein

CHRM1

Drugbank entries Show/Hide entries for Olanzapine or CHRM1
Comment Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors: serotonin 5HT2A/2C; dopamine D1, D2, D3, and D4; muscarinic M1, M2, M3, M4, and M5; histamine H1; and adrenergic (alpha-1) receptors. The antipsychotic activity of olanzapine is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism of muscarinic, histamine, and adrenergic receptors may explain some adverse effects, such as anticholinergic effects, somnolence, and hypotension. (cited information)
Formal Description
Interaction-ID: 43751

drug/chemical compound

Olanzapine

decreases_activity of

gene/protein

CHRM2

Drugbank entries Show/Hide entries for Olanzapine or CHRM2
Comment Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors: serotonin 5HT2A/2C; dopamine D1, D2, D3, and D4; muscarinic M1, M2, M3, M4, and M5; histamine H1; and adrenergic (alpha-1) receptors. The antipsychotic activity of olanzapine is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism of muscarinic, histamine, and adrenergic receptors may explain some adverse effects, such as anticholinergic effects, somnolence, and hypotension. (cited information)
Formal Description
Interaction-ID: 43752

drug/chemical compound

Olanzapine

decreases_activity of

gene/protein

CHRM3

Drugbank entries Show/Hide entries for Olanzapine or CHRM3
Comment Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors: serotonin 5HT2A/2C; dopamine D1, D2, D3, and D4; muscarinic M1, M2, M3, M4, and M5; histamine H1; and adrenergic (alpha-1) receptors. The antipsychotic activity of olanzapine is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism of muscarinic, histamine, and adrenergic receptors may explain some adverse effects, such as anticholinergic effects, somnolence, and hypotension. (cited information)
Formal Description
Interaction-ID: 43753

drug/chemical compound

Olanzapine

decreases_activity of

gene/protein

CHRM4

Drugbank entries Show/Hide entries for Olanzapine or CHRM4
Comment Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors: serotonin 5HT2A/2C; dopamine D1, D2, D3, and D4; muscarinic M1, M2, M3, M4, and M5; histamine H1; and adrenergic (alpha-1) receptors. The antipsychotic activity of olanzapine is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism of muscarinic, histamine, and adrenergic receptors may explain some adverse effects, such as anticholinergic effects, somnolence, and hypotension. (cited information)
Formal Description
Interaction-ID: 43754

drug/chemical compound

Olanzapine

decreases_activity of

gene/protein

CHRM5

Drugbank entries Show/Hide entries for Olanzapine or CHRM5
Comment Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors: serotonin 5HT2A/2C; dopamine D1, D2, D3, and D4; muscarinic M1, M2, M3, M4, and M5; histamine H1; and adrenergic (alpha-1) receptors. The antipsychotic activity of olanzapine is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism of muscarinic, histamine, and adrenergic receptors may explain some adverse effects, such as anticholinergic effects, somnolence, and hypotension. (cited information)
Formal Description
Interaction-ID: 43755

drug/chemical compound

Olanzapine

decreases_activity of

gene/protein

HRH1

Drugbank entries Show/Hide entries for Olanzapine or HRH1
Comment Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors: serotonin 5HT2A/2C; dopamine D1, D2, D3, and D4; muscarinic M1, M2, M3, M4, and M5; histamine H1; and adrenergic (alpha-1) receptors. The antipsychotic activity of olanzapine is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism of muscarinic, histamine, and adrenergic receptors may explain some adverse effects, such as anticholinergic effects, somnolence, and hypotension. (cited information)
Formal Description
Interaction-ID: 43756

drug/chemical compound

Olanzapine

decreases_activity of

gene/protein

ADRA1A

Drugbank entries Show/Hide entries for Olanzapine or ADRA1A
Comment Olanzapine is extensively distributed throughout the body. It is 93% bound to plasma proteins, binding primarily to albumin and alpha-1 acid glycoprotein. It is extensively metabolized in the liver primarily by direct glucuronidation and by oxidation mediated through the cytochrome p450 isoenzymes CYP1A2 and, to a lesser extent, CYP2D6 and CYP3A4. (cited information)
Formal Description
Interaction-ID: 43757

gene/protein

CYP1A2

decreases_quantity of

drug/chemical compound

Olanzapine

in liver
Drugbank entries Show/Hide entries for CYP1A2 or Olanzapine
Comment Olanzapine is extensively distributed throughout the body. It is 93% bound to plasma proteins, binding primarily to albumin and alpha-1 acid glycoprotein. It is extensively metabolized in the liver primarily by direct glucuronidation and by oxidation mediated through the cytochrome p450 isoenzymes CYP1A2 and, to a lesser extent, CYP2D6 and CYP3A4. (cited information)
Formal Description
Interaction-ID: 43758

gene/protein

CYP2D6

decreases_quantity of

drug/chemical compound

Olanzapine

in liver
Drugbank entries Show/Hide entries for
Comment Olanzapine is extensively distributed throughout the body. It is 93% bound to plasma proteins, binding primarily to albumin and alpha-1 acid glycoprotein. It is extensively metabolized in the liver primarily by direct glucuronidation and by oxidation mediated through the cytochrome p450 isoenzymes CYP1A2 and, to a lesser extent, CYP2D6 and CYP3A4. (cited information)
Formal Description
Interaction-ID: 43759

gene/protein

CYP3A4

decreases_quantity of

drug/chemical compound

Olanzapine

in liver
Drugbank entries Show/Hide entries for CYP3A4 or Olanzapine